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Type 2 diabetes mellitus (T2DM) is a highly prevalent disease worldwide. Cardiovascular
disorders generated as a consequence of T2DM are a major cause of death related
to this disease. Diabetic cardiomyopathy (DCM) is characterized by the morphological,
functional and metabolic changes in the heart produced as a complication of T2DM.
This cardiac disorder is characterized by constant high blood glucose and lipids
levels which eventually generate oxidative stress, defective calcium handling, altered
mitochondrial function, inflammation and fibrosis. In this context, insulin is of paramount
importance for cardiac contractility, growth and metabolism and therefore, an impaired
insulin signaling plays a critical role in the DCM development. However, the exact
pathophysiological mechanisms leading to DCM are still a matter of study. Despite the
numerous questions raised in the study of DCM, there have also been important findings,
such as the role of micro-RNAs (miRNAs), which can not only have the potential of being
important biomarkers, but also therapeutic targets. Furthermore, exosomes also arise
as an interesting variable to consider, since they represent an important inter-cellular
communication mechanism and therefore, they may explain many aspects of the
pathophysiology of DCM and their study may lead to the development of therapeutic
agents capable of improving insulin signaling. In addition, adenosine and adenosine
receptors (ARs) may also play an important role in DCM.Moreover, the possible cross-talk
between insulin and ARs may provide new strategies to reverse its defective signaling in
the diabetic heart. This review focuses on DCM, the role of insulin in this pathology and
the discussion of new molecular insights which may help to understand its underlying
mechanisms and generate possible new therapeutic strategies.
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DIABETIC CARDIOMYOPATHY: PATHOPHYSIOLOGY
AND CLINICAL FEATURES
Over the past two decades, the prevalence of type 2 diabetes mellitus (T2DM) has steadily
increased as a consequence of higher rates of obesity, an increase in sedentary lifestyle, and
changes in the environment. If unaddressed, nearly half a billion people will be burdened by this
chronic disease in 2030 (Shaw et al., 2010). At one time, whether T2DM contributed to cardiac
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dysfunction in diabetic patients was a matter of debate (Rubler
et al., 1972). However, diabetic cardiomyopathy (DCM)—
with a prevalence of 12% in T2DM patients (Bertoni et al.,
2004)—is now recognized as a serious complication of T2DM
resulting from sustained hyperglycaemia and hyperlipidemia
that leads to increases in cardiac oxidative stress, inflammation,
and myocardial fibrosis, as well as detrimental changes in
Ca2+ handling and mitochondrial function (Bugger and Abel,
2014; Jia et al., 2016). Several signaling pathways converge in
the development of DCM, and the goal of finding suitable
therapeutic targets remains a challenge. From a clinical
standpoint, DCM is defined as the presence of left ventricular
(LV) dysfunction in patients with T2DM in the absence of arterial
hypertension, coronary artery disease (CAD) or evidence of any
other structural cardiac disease (Battiprolu et al., 2010, 2013;
Maisch et al., 2011; Adeghate and Singh, 2014; Isfort et al., 2014).
Its clinical presentation ranges from early-stage DCM, which
is characterized by abnormal myocardial energy metabolism,
diastolic dysfunction and reduced LV strain to overt heart failure
(HF), associated with cardiomyocyte hypertrophy, myocardial
fibrosis and cardiomyocyte death (Voulgari et al., 2010; Falcao-
Pires and Leite-Moreira, 2012; Battiprolu et al., 2013; Dhalla et al.,
2014; Go et al., 2014; Isfort et al., 2014).
The first stage of DCM is clinically asymptomatic, but is
evidenced by a characteristic diastolic dysfunction (increased
ventricular stiffness, left atrial enlargement, and elevated LV
end-diastolic pressure) (Battiprolu et al., 2010). The prevalence
of diastolic dysfunction is several times higher in T2DM
patients than in sex- and age-matched populations and can
impact up to 40% of T2DM patients (Poulsen et al., 2010).
Several mechanisms contribute to ventricular stiffness in T2DM:
for instance, sustained hyperglycemia promotes formation of
advanced glycation end products (AGEs), which are particularly
prone to cross-linking with extracellular proteins, such as
collagen and elastin, altering their structural properties and
impairing cardiac relaxation (Murarka and Movahed, 2010; Jia
et al., 2016).
The second stage of DCM is characterized by cardiac
remodeling, LV hypertrophy (LVH), and the emergence of
clinical indications of HF (Ozasa et al., 2008); however, whether
LV systolic dysfunction ultimately develops is a matter of
debate. Although some authors have suggested that there is
an association between systolic dysfunction and long-standing
diabetes (Mbanya et al., 2001), most publications indicate
that resting systolic function is normal in the majority of
T2DM patients, as assessed by LV ejection fraction (LVEF),
although some subjects may exhibit systolic impairment during
exercise (Vered et al., 1984). However, LVEF can be a poor
approximation of cardiac contractility and may not detect
minor changes in myocardial function (Sonoyama et al., 2007).
These abnormalities in myocardial function correlate closely
with changes in Ca2+ handling, caused in part by AGEs
that decrease mechanical efficiency of the sarcomere and
impair electromechanical coupling, ultimately leading to reduced
contractility (Bugger and Abel, 2014). In addition, the activity
of the sarco(endo)plasmic reticulum Ca2+-ATPase isoform
2 (SERCA2), the ryanodine receptor (RyR) and Na+/Ca2+
exchanger (NCX1) are markedly reduced in DCM, leading to
diminished release of Ca2+ from endoplasmic reticulum stores
and slowed replenishment of these stores during relaxation.
These changes, in turn, lead to elevated end-diastolic Ca2+ levels
and a progressive decrease in the frequency of Ca2+ transients
(Zhao et al., 2014). There is evidence that hyperglycemia may
activate caspase-3 directly (Cai et al., 2002) causing apoptosis
of cardiomyocytes and increased interstitial fibrosis (Fiordaliso
et al., 2000). Thus, increased cardiomyocyte apoptosis may
be a critical step in the transition from compensated to
decompensated HF (Frustaci et al., 2000). It has also been
proposed that insulin-resistance in DCM may be related to
increased risk of cardiac LVH or HF (Abel et al., 2012). Altered
myocardial insulin signaling is a hallmark of DCM (Battiprolu
et al., 2012; Bugger and Abel, 2014; Jia et al., 2016); however, the
molecular mechanisms that have been proposed to contribute
to the development of insulin resistance in DCM are not fully
understood. In this review, we summarize the current knowledge
about cardiac insulin signaling, with emphasis on new molecular
insights regarding its role in DCM.
INSULIN SIGNALING IN THE NORMAL
HEART
An appreciation for the role of insulin in glucose homeostasis
began with its discovery in 1922 (Banting et al., 1922). The
ability of insulin to induce glucose uptake (Levine et al., 1949)
by activating specific cell surface receptors on target tissues
(Kahn et al., 1974; Ebina et al., 1985; Ullrich et al., 1985),
thus, triggering the translocation of the glucose transporter 4
(GLUT4) to the plasma membrane (Cushman and Wardzala,
1980; Suzuki and Kono, 1980), is well documented. However,
much remains to be learned regarding both the physiological and
pathophysiological impact of insulin signaling in the diversity
of tissues, such as adipose tissue and skeletal muscle, upon
which it acts (Leto and Saltiel, 2012). Although a comprehensive
understanding of the mechanisms underlying insulin action in
the heart is only just emerging, there is abundant evidence
that insulin impacts cardiac metabolism by influencing a wide
range of cellular processes, such as glucose transport, glycolysis,
glycogen synthesis (Abel, 2004), cardiac hypertrophy, protein
synthesis, lipid metabolism (Belke et al., 2002). Moreover, insulin
also participates in myocardial contractility (Fu et al., 2014),
protection against ischemia-induced necrotic death (Diaz et al.,
2015), autophagy (Riehle et al., 2013), and cell survival, either
directly or through the closely associated insulin-like growth
factor-1 (IGF-1) (Troncoso et al., 2014).
Cardiac Metabolism
Insulin-stimulated glucose uptake in cardiomyocytes is mediated
primarily through mobilization of glucose transporter 4
(GLUT4). Basal cardiac glucose uptake is mediated by glucose
transporter 1 (GLUT1), however, contraction-mediated
activation of GLUT4 translocation may also contribute
significantly to myocardial glucose uptake (Abel, 2004).
We have reported that GLUT4-mediated glucose uptake
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FIGURE 1 | Insulin signaling in the normal heart and diabetic cardiomyopathy. (A) Insulin binding to its receptor (insulin receptor, IR) promotes a biphasic
[Ca2+]i response in cardiomyocytes. The first phase of insulin-dependent [Ca
2+]i increase involves extracellular Ca
2+ influx through L-type calcium channel (LTCC)
and activation of ryanodine receptor (RyR) Ca2+ channel which in turn releases Ca2+ from the sarcoendoplasmic reticulum (SR). The second phase involves a
non-inhibitory G protein coupled receptor (Gβγ subunits) that activates downstream effectors, including phosphatidylinositol 3-kinase (PI3K)γ and phospholipase C
(PLC). PLC generates inositol-1,4,5-trisphosphate (IP3) that opens the IP3-ligated Ca
2+channels in the SR. These mechanisms trigger the translocation of glucose
transporter 4 (GLUT4) from an intracellular store to the plasma membrane (PM) and increase glucose uptake. Insulin also induces the translocation of the fatty acid
(FA) transporter FAT/CD36 to the PM trough PI3K activation promoting the FA uptake. Increased lipid and glucose uptake increase mitochondrial oxidative metabolism
generating adenosine triphosphate (ATP) that supports myocardial contractile function. Insulin activation of AKT, downstream of PI3K, inactivates the transcription
factor FoxO1. In addition, miR-223 stimulates and miR-133 reduces GLUT4-dependent glucose uptake. (B) Insulin signaling is deficient in diabetic cardiomyopathy
(DCM). FoxO1-dependent downregulation of insulin receptor substrate 1 (IRS1) and AKT are associated with reduced insulin-induced GLUT4 translocation to the PM
and lower glucose uptake. At the same time, cardiomyocytes accumulate lipids, reducing mitochondrial oxidative metabolism and promoting mitochondrial
uncoupling, which in turn, affects cardiomyocyte function. Also, miR-143 inhibits insulin signaling, whereas miR-141 may impact mitochondrial function and the
production of ATP. On the other hand, miR-451 is associated with inhibition of AMPK, while miR-195 inhibits the expression of BCL-2 and SIRT-1. Both of these
miRNAs are associated with hypertrophy, which will consequently generate contractile dysfunction. Adenosine may have a paracrine effect on cardiomyocytes, which
could reduce hypertrophy and myocardial fibrosis through the activation of adenosine receptors (ARs). Exosomes can ferry miRNAs and proteins such as GLUT4 from
one cell to another and therefore, they can be used as potential biomarkers or therapeutic agents/targets for DCM.
in cardiomyocytes can be activated through a G protein,
phosphatidylinositol 3-kinase (PI3K)γ and 1,4,5-inositol-
triphosphate (IP3) receptor (IP3R) signaling axis, leading
to generation of a cytoplasmic Ca+2 signal that mobilizes
GLUT4 (Contreras-Ferrat et al., 2010; Figure 1A). Although
the mechanisms of insulin regulation of cardiac GLUT4
are not yet fully defined, recent data show that constitutive
activation of PI3K and AKT can reduce glucose uptake in
mouse cardiomyocytes through a mechanism that does not
involve GLUT4 translocation, suggesting that insulin impacts
GLUT4 activity beyond the ability to regulate translocation
to the plasma membrane (Zhu et al., 2013a). Moreover, in
the heart of mice with a cardiomyocyte-selective deletion
of GLUT4 (G4H−/−), there was a reduction in the levels of
insulin-responsive aminopeptidase (IRAP) which was related
to impaired GLUT4 endosomal trafficking (Abel et al., 2004),
further suggesting that GLUT4 may play a role in regulating
glycolysis beyond its ability to transport glucose (Tian and Abel,
2001), evidence that highlight the critical role of GLUT4 and
GLUT1 in the insulin-mediated glucose transport on cardiac
metabolism.
Cardiac Contractility
Several animal studies have shown the cardioprotective effects of
insulin (Das, 2003). In addition, clinical studies have suggested
an association between insulin resistance and HF (Arnlov et al.,
2001; Ingelsson et al., 2005). However, excessive cardiac insulin
signaling can exacerbate systolic dysfunction induced by pressure
overload in mice (Shimizu et al., 2010). Cardiac specific insulin
receptor knockout (CIRKO) hearts show a mild reduction in
cardiac function (Belke et al., 2002) and developed more severe
contractile dysfunction compared with control hearts in response
to isoproterenol exposure, a combined β1- and β2-adrenergic
receptor (βAR) agonist (McQueen et al., 2005). Fu et al. proposed
an interesting model for crosstalk between the insulin receptor
(IR) and β2AR signaling in the heart (complex IR/β2AR) that
could impact cardiac contractility (Fu et al., 2014). In their model,
increased IR signaling promotes dissociation of the IR/β2AR
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complex, leading to an impaired contractile response to β2AR
subsequent activation. This effect was seen in isolated neonatal
and adult cardiomyocytes, as well as Langendorff-perfused hearts
(Fu et al., 2014). Moreover, CIRKO mice, which are deficient
for IR signaling, display defective electrical impulse propagation,
elevated K+ extracellular concentrations (Punske et al., 2004),
and diminished levels of several key K+ channel components
involved in ventricular repolarization (Lopez-Izquierdo et al.,
2014). Moreover, insulin can diminish markers of cytosolic
oxidative stress (Li et al., 2012) and improve impaired cardiac
electrical activity during hypoxia in G4H−/− hearts (Sohn et al.,
2013). Altogether, this evidence suggests a link between insulin
signaling and the electrical function in the heart independent of
its activation of GLUT4-dependent glucose uptake.
Cardiac Growth
In the adult heart, myocardial growth is achieved primarily
through hypertrophic expansion of individual cardiomyocytes
(Pasumarthi and Field, 2002). Heart size increases during post-
natal development in response to several stimuli (Olson and
Schneider, 2003), and these responses can be classified either
as “pathological” or “physiological” (Richey and Brown, 1998).
Insulin is considered an anabolic hormone that promotes
protein synthesis, cell growth and hypertrophy (Shiojima
et al., 2002). CIRKO mice are characterized by a 30%
reduction in heart size (Belke et al., 2002), consistent with
the effects observed in cardiomyocytes with reduced PI3K/AKT
signaling, where insulin-stimulated hypertrophy is blunted (Shioi
et al., 2000; Shiojima et al., 2002). G4H−/− mice developed
modest cardiac hypertrophy, with preserved contractile function,
that is associated with an increase in cardiomyocyte size
(Abel et al., 1999). Another study conducted by O’Neill
et al. suggests that PI3K activates AKT-independent signaling
pathways that mediate metabolic and mitochondrial adaptations
during physiological cardiac hypertrophy (O’Neill et al.,
2007). Cardiomyocyte-specific overexpression of constitutively
activated mechanistic target of rapamycin (mTOR), an important
target and modulator of the insulin-stimulated AKT pathway,
did not elicit a significant increase in adult heart weight
(Shen et al., 2008), even though mTOR is essential for
cardiac development and growth during embryogenesis (Zhu
et al., 2013b). Cardiomyocytes treated with the peroxisome
proliferator-activated receptor (PPAR)γ agonist troglitazone also
respond by increasing protein content (Bell and Mcdermott,
2000); however, the hypertrophic response of cardiomyocytes to
PPARγ agonists does not appear to be mediated by changes in
myocardial insulin signaling (Sena et al., 2007).
Studies of mice with cardiomyocyte-specific deletion of either
insulin receptor substrate 1 (IRS1) (CIRS1KO mice) or IRS2
(CIRS2KO mice) reported that at baseline, adult CIRS1KO
hearts were reduced in size, whereas CIRS2KO hearts exhibited
cardiac hypertrophy. However, following a swim training exercise
regimen, mitochondrial capacity and substrate oxidation rates
increased in wild-type controls, but not in IRS-deficient hearts,
suggesting that although different IRS isoforms may perform
different roles during resting conditions, both are required for
the hypertrophic and metabolic adaptation to exercise (Riehle
et al., 2014). In summary, these studies suggest an important role
for insulin signaling in physiological cardiac growth, however
studies by Ikeda et al. indicated that in response to exercise
IGF-1 may actually activate both the IGF-1 receptor (IGF-1R)
and IR in the heart (Ikeda et al., 2009). Thus, deciphering the
crosstalk between the IGF-1 and insulin signaling pathways will
be crucial to understanding the role of IR in exercise-induced
cardiac hypertrophy.
INSULIN SIGNALING IN DIABETIC
CARDIOMYOPATHY
Defective insulin signaling in DCM has been described in
both animal models (Wright et al., 2009) and humans (Cook
et al., 2010), primarily observed as reduced GLUT4 translocation
to the plasma membrane. Cardiac dysfunction induced by
pressure overload in mice is associated with insulin resistance,
hyperinsulinemia and increased AKT activation (Shimizu et al.,
2010). Hearts from obese and insulin-resistant rodent models
(ob/ob and db/db mice) exhibit higher rates of fatty acid (FA)
oxidation and MVO2, but lower rates of glucose oxidation
and cardiac efficiency, which precede the development of
hyperglycemia (Mazumder et al., 2004; Buchanan et al., 2005).
Moreover, CIRKOmice exhibit decreased LV function associated
with mitochondrial dysfunction and reduced mitochondrial FA
oxidative capacity following a myocardial infarct (Sena et al.,
2009), as well as an enhanced decline in cardiac function when
treated with streptozotocin (STZ) compared to wild-type mice
(Bugger et al., 2012). In addition, these animals have defects in
FA and pyruvate metabolism and reduced tricarboxylic acid flux
associated with mitochondrial uncoupling. Thus, altered insulin
signaling in the heart may contribute directly to mitochondrial
dysfunction in the setting of obesity and T2DM (Boudina
et al., 2009). In contrast, the type 1 diabetic Akita mouse
model (Akita) is characterized by normal cardiac function and
preservedmyocardial insulin sensitivity, and does not exhibit FA-
induced mitochondrial uncoupling (Bugger et al., 2008). These
results suggest that the activity of pathways controlling cardiac
mitochondrial function may be different in insulin-responsive
type 1 and insulin-resistant T2DM hearts.
Interestingly, FoxO (forkhead box-containing protein, O
subfamily) proteins have been described as important regulators
of several cellular processes in the myocardium such as cardiac
growth (Skurk et al., 2005; Ni et al., 2006), and autophagy
(Sengupta et al., 2009; Schips et al., 2011). In addition, Ni
et al. (2007) showed that FoxO activation leads to altered
insulin signaling and decreased glucose uptake in cardiac
myocytes (Ni et al., 2007). In this sense, activation of FoxO1 in
response to the HFD was directly related to down-regulation of
IRS1 activity, decreased AKT signaling, and insulin resistance,
suggesting that FoxO1 might be a key step in the development
of DCM preventing cardiac dysfunction by restoring insulin
responsiveness (Battiprolu et al., 2012; Figure 1B). Recently,
it has been shown that impaired cardiac insulin signaling
FoxO1-mediated stimulates the β-myosin heavy chain (β-MHC)
expression promoting cardiac dysfunction (Qi et al., 2015). Thus,
Frontiers in Physiology | www.frontiersin.org 4 April 2016 | Volume 7 | Article 125
Westermeier et al. Insulin and Diabetic Cardiomyopathy
FoxO1 plays a key role in the control of cardiac insulin signaling
both in physiological and pathophysiological conditions, and
it might prove a novel therapeutic or preventive strategy for
treating individuals with DCM.
On the other hand, FAs are the major substrate for ATP
synthesis in the heart; nevertheless, excess lipid accumulation
is associated with decreased cardiac function in obesity and
diabetes (Finck et al., 2002, 2003). In this context, insulin is
also able to induce FA uptake in cardiomyocytes, promoting the
translocation of the FA transporter FAT/CD36 (Glatz et al., 2006;
Coort et al., 2007) to the plasma membrane mediated by PI3K
activation (Luiken et al., 2002; Figure 1A). Overexpression of
PPARγ led to cardiac lipid accumulation and cardiomyopathy
associated with increased FAT/CD36 mRNA, but this effect
was antagonized by WY-14,643, a potent PPARα agonist (Son
et al., 2010). Nevertheless, comprehensive understanding of the
relationship between PPARs and insulin in DCM are not yet
fully understood (Jia et al., 2016). The heart can metabolize
either non-esterified FA (bound to albumin) or FA obtained
from lipolysis of lipoprotein-bound triglycerides (TG). Hearts
from mice with cardiomyocyte-specific knockout of lipoprotein
lipase (LpL) showed reduced FA oxidation and increased glucose
oxidation, associated with increased expression of GLUT4, and
reduced expression of pyruvate dehydrogenase kinase 4 (PDK4),
suggesting that heart is able to adapt by balancing between the use
of glucose and FA (Augustus et al., 2006). However, recent studies
indicate that deletion of mTOR impairs myocardial palmitate
oxidation and reduces expression of several genes associated
with FA metabolism while also reducing insulin-stimulated AKT
Ser473 phosphorylation (Zhu et al., 2013c). Thus, intact mTOR
signaling may be essential for maintaining appropriate control
over substrate usage. In addition, cardiomyocytes from HFD-
fed mice exhibit increased FA oxidation rates and myocardial
oxygen consumption (MVO2), correlating with reduced GLUT4
content and impaired GLUT4 translocation in response to
insulin (Wright et al., 2009; Figure 1B) and consistent with
earlier studies involving the response of cardiomyocytes to the
adipocytokine resistin (Graveleau et al., 2005). In summary,
cardiac lipotoxicity involves detrimental effects that may




miRNAs are small, single-strand non-coding RNA, that are
transcribed by RNA polymerase II (Pol II), generating a primary
miRNA (pri-miRNA). In the nucleus, the RNase III endonuclease
Drosha and the double-stranded RNA-binding domain protein
DGCR8/Pasha cleave the pri-miRNA to produce the precursor
miRNA (pre-miRNA) of ∼70-nt. Exportin-5 transports the pre-
miRNA into the cytoplasm, where it is cleaved by another
RNase III endonuclease, Dicer, together with the protein
TRBP/Loquacious, releasing miRNA containing a 21- to 23-
nt (Bushati and Cohen, 2007; Pasquinelli, 2012). They serve
as important post-transcriptional regulators that down-regulate
the expression of their target genes (Pritchard et al., 2012) The
exact and detailed role of miRNAs in the heart is far from
being completely understood, but there is mounting evidence
showing that alterations in many miRNAs correlate with the
development and progression of human diseases, including
cardiovascular diseases, such as DCM (Asrih and Steffens, 2013).
In this context, Zheng et al. (2015) found that miR-195 is up-
regulated in the hearts of C57BL/6mice treated with STZ and this
was associated with a decrease expression of its target proteins
B cell leukemia/lymphoma 2 (BCL-2) and sirtuin 1 (SIRT-1)
(Zheng et al., 2015). Moreover, inhibition of miR-195 inhibited
apoptosis, reduced oxidative stress and hypertrophy in diabetic
hearts. Additionally, cardiac function and coronary blood flow
was improved and the expression of BCL-2 and SIRT-1 was
increased, suggesting that targetingmiR-195may attenuate DCM
(Zheng et al., 2015). In order to further elaborate on the subject,
we briefly discuss about a few miRNAs and their potential role
in DCM. The models used, beneficial or detrimental effect on
cardiac function and possible mechanisms suggested so far are
summarized in Table 1.
miR-133a,b expression have been shown to participate in
metabolic control by reducing the expression of GLUT4 and
insulin-mediated glucose uptake in neonatal rat cardiomyocytes
(NRCs) (Horie et al., 2009). In contrast, Chen et al. (2014) found
that miR-133a expression was reduced in the hearts of diabetic
mice and this was associated with an increase in the expression
of fibrosis markers. Moreover, they observed that overexpression
of miR-133a in the heart attenuated cardiac fibrosis, which is one
of the central causes for the HF generated by DCM (Chen et al.,
2014). Considering the apparent contradiction between these
two studies performed in different models, the results should be
analyzed with precaution and further in vivo studies are required
to fully clarify the role of miR-133a in DCM.
On the other hand, overexpression of miR-223 in NRCs
significantly increased glucose uptake, in similar magnitude
to that observed in cells stimulated with insulin. In vitro,
overexpression of miR-223 in cardiomyocytes increased total
GLUT4 level and induced GLUT4 translocation from the
cytoplasmic compartment to the cell membrane. In vivo,
inhibition of miR-223 in the heart resulted in a significant
decrease in GLUT4 expression (Lu et al., 2010). miR-141
may be another miRNA of importance in DCM, since it
was found to be significantly increased in the diabetic heart
and its overexpression decreased the content of the inner
mitochondrial membrane phosphate transporter, solute carrier
family 25 member 3 (Slc25a3) in the mouse atrial cardiomyocyte
cell line HL-1 (Baseler et al., 2012), suggesting that altered miR-
141 expression may influence cardiac mitochondrial function
and ATP generation (Baseler et al., 2012).
Further extending the evidence for the role of miRNA in
the pathophysiology DCM, miR-451 levels were found to be
markedly increased in palmitate-stimulated NRCs and DIO
mouse heart (model of pre-T2DM and obesity with elevated
blood glucose and impaired glucose tolerance). It was found that
Cab39 (Calcium-binding protein 39, a scaffold protein of LKB1,
a kinase upstream of AMPK) was a direct target to miR-451
in the heart. Furthermore, miR-451 knockdown partly rescued
lipotoxicity in vitro, and HFD-induced cardiac hypertrophy was
ameliorated in miR-451 KO mice through the LKB1/AMPK
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195 STZ mice ↓ ↑ Apoptosis
↑ Oxidative stress
↑ Hypertrophy
↓ Coronary blood flow
Zheng et al., 2015
133a,b NRCs ↓ ↓ Glucose uptake Horie et al., 2009
133a STZ mice ↑ ↓ TGF-β1
↓ SMAD2
↓ p-ERK1/2
Chen et al., 2014
223 NRCs ↑ ↑ Glucose uptake Lu et al., 2010
141 HL-1, STZ mice ↓ ↓ ATP production Baseler et al., 2012
451 HFD-fed mice, NRCs ↓ ↓ LKB1/AMPK Kuwabara et al., 2015
143 HL-1, ARCs ↓ ↓ p-AKT
↓ ORP8
↓ Glucose uptake
Blumensatt et al., 2013
29a,b,c HL-1, ZDF rat ↓ ↓ mTORC1/MCL-1 Arnold et al., 2014
322 ob/ob mice ↑ ↓ p-AKT Marchand et al., 2016
Abbreviations: AKT, protein kinase B; AMPK, AMP-activated protein kinase; ARCs, adult rat cardiomyocytes; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; LKB1, liver
kinase B1; MCL-1, myeloid leukemia cell differentiation protein; mTORC1, mammalian target of rapamycin complex 1; NRCs, neonatal rat cardiomyocytes; ORP8, Oxysterol-binding
protein-related protein 8; SMAD2, SMAD family member 1; STZ, streptozotocin; TGF-b1, transforming growth factor beta 1; ZDF, Zucker Diabetic Fatty rat. ↓, Decreased; ↑, Increased.
pathway (Kuwabara et al., 2015). Moreover, activin A released
from epicardial adipose tissue in T2DM, inhibits insulin action
via the induction of miR-143 in cardiomyocytes. This miRNA
inhibits the AKT pathway through down-regulation of the novel
regulator of insulin action, ORP8 (Blumensatt et al., 2013).
ORP8 binds 25-OH-cholesterol, and this regulates AKT signaling
in apoptosis through the induction of AKT degradation via
proteasome and/or inhibition of PI3K in macrophages (Jordan
et al., 2011). Moreover, activation of AKT in response to insulin
and the consequent phosphorylation of glycogen synthase kinase
3β (GSK3β) were diminished in HepG2 cells depleted of ORP8
(Jordan et al., 2011). Future studies should confirm these results
in the heart to further clarify the role of miR-143 and ORP8
in DCM.
Regarding insulin, it has been shown that miR-29, which
downregulates the pro-survival protein myeloid cell leukemia
1 (MCL-1) (Roggli et al., 2012), may be involved in the
development of DCM. Arnold et al., reported that insulin
inhibited the expression of miR-29a, b and c and increased
the mRNA levels of MCL-1 in HL-1 cells. Additionally,
they observed that dysregulation of the miR-29-MCL-1 axis
as a consequence of low levels of insulin or inhibition of
mTORC1 in Zucker Diabetic Fatty (ZDF) rats was associated
with structural damage of the diabetic myocardium (Arnold
et al., 2014). In addition, Marchand et al. have recently
reported that miR-322 modulates insulin pathway, protecting
the heart against the cardiac dysfunction observed in C57Bl/6N
mice fed with HFD, showing that miR-322 overexpression
reduced AKT phosphorylation induced by insulin. Thus, miR-
322 regulates insulin signaling and might protect the heart
against consequences of hyperinsulinemia (Marchand et al.,
2016). Moreover, Costantino et al. showed that altered miRs
profile induced by hyperglycaemia in the diabetic heart is
not reverted by the restoration of normal glycaemia levels
with insulin (Costantino et al., 2016). This study also showed
through ingenuity pathway analysis that the miRs increased in
the diabetic heart were involved in myocardial cell signaling
pathways associated with apoptosis, fibrosis, hypertrophic
growth, autophagy, oxidative stress, and HF and this may explain
why the detrimental effects of DCM persist even after the
restoration of normal glucose levels (Costantino et al., 2016).
Considering all the evidence shown above, miRNAs clearly
participate in the pathophysiological mechanisms involved in
DCM and more studies are required to fully understand and
control their diagnostic and therapeutic potential.
Exosomes
Exosomes are nanosized extracellular vesicles ranging from
50 to 90 nm in diameter. These nanovesicles are formed
in multivesicular bodies, which after fusing with the plasma
membrane; release their content to the extracellular medium
(Thery et al., 2006). Exosomes can carry proteins, RNA or
miRNA from one cell to another through the bloodstream,
protecting its content from enzymatic degradation and thus,
these extracellular vesicles may be mediating intercellular
communications (Yellon and Davidson, 2014). Moreover, de
Jong et al reported that cellular stress may induce variations
in the protein and mRNA content of endothelial cell-derived
exosomes (De Jong et al., 2012), which suggests that exosomes
may represent the physiological state of the cell (Yellon and
Davidson, 2014). Therefore, exosomes are a very attractive target
to develop possible biomarkers for different diseases.
The potential role of exosomes in cardiovascular diseases is
starting to be explored. In this context, it has been described
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that exosomes exert a cardioprotective effect in the myocardium
against ischemia-reperfusion (Giricz et al., 2014; Vicencio et al.,
2015). It has also been reported that exosomes may play a role
in septic cardiomyopathy, cardiac hypertrophy, and peripartum
cardiomyopathy (Ailawadi et al., 2015).
Regarding DCM and the importance of miRNAs in
this disease, exosomes arise as potential biomarkers for
diagnosis. However, much remains to be elucidated about these
nanovesicles and their role in DCM. In this context, it has
been suggested that most of the plasma miRNAs are contained
in exosomes, however, it has also been reported that plasma
miRNAs can be bound to complexes of proteins like argonaute
or high density lipoproteins (Yellon and Davidson, 2014) and
therefore, further studies are required to clarify this point.
In the context of understanding the mechanisms involved
in diabetes-induced ischemic cardiac disease (Ailawadi et al.,
2015), Wang et al showed that cardiomyocyte-derived exosomes
isolated from Goto-Kakizaki (GK) diabetic rats inhibited the
proliferation and migration of endothelial cells. Interestingly,
exosomes isolated from Wistar rat’s cardiomyocytes generated
the opposite effect in the endothelial cells, promoting migration
and proliferation. In addition, the effects of both GK and Wistar
rat’s exosomes on endothelial cells were reversed by the exosome
inhibitor GW4869. Moreover, GK-exosomes contained higher
levels of miR-320 and lower levels of miR-126 compared to
Wistar rat’s cardiomyocyte-derived exosomes (Wang et al., 2014).
Therefore, these results suggest that reduced angiogenesis in
the diabetic myocardium may be mediated by exosomes with
anti-angiogenic effects released from cardiomyocytes to the
endothelium. These findings also suggest a possible role for
exosomes for the treatment of DCM ischemic complications.
It has also been recently reported that cardiomyocyte-
derived exosomes can regulate glucose transport in endothelial
cells (Garcia et al., 2016). This study showed that under
glucose deprivation conditions, the production of exosomes from
cardiomyocytes was increased and these nanovesicles contained
glucose transporters and enzymes involved in glycolysis, which
in turn lead to an increase in glucose uptake, glycolysis and
the production of pyruvate in the endothelial cells (Garcia
et al., 2016). Taken the current evidence together, exosomes
have massive potential to give new insights that could help
to understand the pathophysiology of DCM and they can not
only serve as potential biomarkers, but also act as therapeutic
targets or agents that could reverse the impaired insulin signaling
observed in DCM.
Adenosine
The purine nucleoside adenosine is an important
paracrine/autocrine signaling molecule that modulates a
wide range of biological processes activating four subtypes of
G protein-coupled adenosine receptors (ARs), A1, A2A, A2B,
and A3 (Fredholm, 2014). The ARs play a key role in tissue
homeostasis both in physiological and pathophysiological
conditions, such as inflammation, ischemia, hypoxia and cancer,
regulating tissue homeostasis (Antonioli et al., 2013).
Interestingly, new evidence has emerged suggesting a link
between adenosine signaling and T2DM (Antonioli et al., 2015).
In this context, it has been described that adenosine modulates
insulin secretion (Johansson et al., 2007; Yang et al., 2012; Ohtani
et al., 2013) and also controls the proliferation and regeneration
of β pancreatic cells (Ohtani et al., 2013; Andersson, 2014).
Moreover, several studies have proposed that adenosine regulates
the insulin signaling in muscle (Faulhaber-Walter et al., 2011;
Figler et al., 2011; Johnston-Cox et al., 2012), liver (Figler et al.,
2011; Johnston-Cox et al., 2012), and adipose tissue (Faulhaber-
Walter et al., 2011; Figler et al., 2011; Johnston-Cox et al., 2012;
Csoka et al., 2014).
In the cardiovascular system, the expression of ARs have been
reported in vascular smooth muscle cells (Zhao et al., 1997),
human umbilical vein endothelial cells (Wyatt et al., 2002),
coronary artery endothelial cells (Olanrewaju et al., 2000), cardiac
fibroblasts and cardiomyocytes (Sassi et al., 2014). In STZ-treated
diabetic rats, cardiomyocytes exhibited increased levels of A1 and
A3, reduced levels of A2A and unaltered levels of A2B (Grden
et al., 2005); however, cardiac fibroblasts showed increased levels
of A1 and A2A,reduced levels of A3 but did not change the levels
of A2B (Grden et al., 2006). Thus, the evidence described above
highlights the need to assess the functional role of ARs in DCM.
As we mentioned before, early-stage DCM is characterized by
cardiomyocyte hypertrophy and myocardial fibrosis (Battiprolu
et al., 2013; Go et al., 2014). In this context, Puhl et al. (2016)
recently showed that A1 attenuates phenylephrine-mediated (α-1
adrenoceptor) cardiomyocyte hypertrophic and cardiac fibrosis,
suggesting that A1 activation might be a novel therapeutic target
to prevent cardiac remodeling (Puhl et al., 2016). In addition,
cell-to-cell communication via cAMP/adenosine activating A1
and A2A/A2B in cardiomyocytes and fibroblast, respectively,
may be also relevant in preventing isoproterenol-mediated
(βAR agonist) cardiomyocyte hypertrophy and cardiac fibrosis,
suggesting an interesting paracrine cardiac action of adenosine
(Sassi et al., 2014). In summary, whether ARs participates in
the molecular mechanisms of DCM, or whether they might
be promoting the DCM-related defective insulin signaling are
important issues that need to be addressed.
CONCLUDING REMARKS AND OPEN
QUESTIONS
The complete pathophysiology of DCM and the role of
insulin in it are still being elucidated. Further studies are
certainly required to clarify many aspects of this cardiovascular
disease. However, there has also been emerging information
on different mechanisms that may help answer the variety
of questions raised in the study of DCM. Despite increasing
amount of evidence that highlights the role of ARs in the
regulation of insulin signaling in several tissues such as muscle,
liver and adipose tissue, there are many open questions to
deeply understand their roles both in the healthy heart and
DCM. Thus, could insulin signaling in DCM be improved
by activation of ARs? In addition, miRNAs may play a key
role for early diagnosis of DCM and evidence such as the
altered miRNA landscape in the diabetic heart suggests that
new strategies are required to reverse the detrimental effects
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of DCM that persists despite normalization of blood glucose
levels. In this context, is it possible to reverse the cardiovascular
complications of DCM by targeting the miRNAs associated
with these deleterious effects? Also, exosomes may also serve
as potential biomarkers of DCM. These nanovesicles are a
mechanism of inter-cellular communication and therefore, there
is much excitement about the possibility of harnessing their
power as therapeutic agents. Could normal exosomes isolated
from healthy patients reverse the phenotype of patients with
DCM? Is it possible to exogenously control the release of
beneficial exosomes? Answers to these questions will help to
elucidate the complex mechanisms underlying the defective
insulin signaling in DCM, opening new fields for basic and
clinical studies.
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